After a spike in current retail value growth in 2020, systemic analgesics is expected to record more moderate growth in 2021. This is reflective of the way in which Canadians used analgesics during the COVID-19 pandemic for a wide variety of purposes, including core pain relief, symptomatic relief (particularly among elderly Canadians) and pain management while waiting for nonurgent, elective surgery, which was postponed as hospitals prioritised COVID-19 cases.
Major global pharmaceutical companies continue to dominate analgesics in Canada. GlaxoSmithKline Consumer Healthcare, a recently formed joint venture between GlaxoSmithKline Plc and Pfizer, is expected to remain the overall leader in current value terms thanks to a broad portfolio covers that multiple categories and well-established brands with trusted reputations for safety and efficacy.
Although store-based retailing is expected to continue to dominate sales of analgesics in Canada in 2021, e-commerce is expected to gain some share thanks to increased availability via online grocery stores during the COVID-19 pandemic. Major grocery retailers, including Walmart, Real Canadian Superstore and Grocery Gateway, all offer systematic analgesics such as Tylenol and Advil.
Canada’s ageing population is the key demographic driver for pain relief and will continue to support category growth over the forecast period. Older Canadians typically suffer from the nagging aches and pains associated with ageing bodies, as well as more aches and pains from physical activity such as exercise, conditions such as arthritis.
Although e-commerce is forecast to post robust percentage growth over the forecast period, in actual dollar terms gains will be muted. E-commerce for OTC Analgesics faces a number of challenges, including varying provincial regulations over what products are allowed to be sold online, widespread availability through mass brick and mortar channels such as hypermarkets, drug stores and supermarkets, and price points that work against online purchases.
CBDs are regulated in Canada under the Cannabis Act, with each province and territory responsible for determining how cannabis is distributed and sold within their jurisdictions. CBD topical analgesics are available through licensed, regulated cannabis sellers as medical cannabis products or as CBD products.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Analgesics industry in Canada with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in Canada, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
This report originates from Passport, our Analgesics research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page